Patents by Inventor David Tomoaki Miyamoto

David Tomoaki Miyamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Digital Analysis of Circulating Tumor Cells in Blood Samples
    Publication number: 20240132969
    Abstract: This disclosure relates to new assay methods for analysis of circulating tumor cells (CTCs) in blood samples for detection, e.g., early detection, and/or monitoring of disease, e.g., cancer. The methods provide ultra-high sensitivity and specificity, and include the use of microfluidic isolation of CTCs and digital detection of RNA derived from the CTCs.
    Type: Application
    Filed: December 26, 2023
    Publication date: April 25, 2024
    Inventors: Daniel A. Haber, Ravi Kapur, Mehmet Toner, Shyamala Maheswaran, Xin Hong, David Tomoaki Miyamoto, Tanya Todorova, Sarah Javaid
  • Digital analysis of circulating tumor cells in blood samples
    Patent number: 11898209
    Abstract: This disclosure relates to new assay methods for analysis of circulating tumor cells (CTCs) in blood samples for detection, e.g., early detection, and/or monitoring of disease, e.g., cancer. The methods provide ultra-high sensitivity and specificity, and include the use of microfluidic isolation of CTCs and digital detection of RNA derived from the CTCs.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: February 13, 2024
    Assignee: The General Hospital Corporation
    Inventors: Daniel A. Haber, Ravi Kapur, Mehmet Toner, Shyamala Maheswaran, Xin Hong, David Tomoaki Miyamoto, Tanya Todorova, Sarah Javaid
  • Digital Analysis of Blood Samples to Determine Efficacy of Cancer Therapies for Specific Cancers
    Publication number: 20220364185
    Abstract: This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.
    Type: Application
    Filed: May 27, 2022
    Publication date: November 17, 2022
    Inventors: Daniel Haber, Shyamala Maheswaran, Tanya Todorova, Mark Kalinich, David Tomoaki Miyamoto, Xin Hong
  • Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
    Patent number: 11371101
    Abstract: This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: June 28, 2022
    Assignee: The General Hospital Corporation
    Inventors: Daniel Haber, Shyamala Maheswaran, Tanya Todorova, Mark Kalinich, David Tomoaki Miyamoto, Xin Hong
  • Digital Analysis of Circulating Tumor Cells in Blood Samples
    Publication number: 20210189501
    Abstract: This disclosure relates to new assay methods for analysis of circulating tumor cells (CTCs) in blood samples for detection, e.g., early detection, and/or monitoring of disease, e.g., cancer. The methods provide ultra-high sensitivity and specificity, and include the use of microfluidic isolation of CTCs and digital detection of RNA derived from the CTCs.
    Type: Application
    Filed: October 8, 2020
    Publication date: June 24, 2021
    Inventors: Daniel A. Haber, Ravi Kapur, Mehmet Toner, Shyamala Maheswaran, Xin Hong, David Tomoaki Miyamoto, Tanya Todorova, Sarah Javaid
  • Digital Analysis of Blood Samples to Determine Efficacy of Cancer Therapies for Specific Cancers
    Publication number: 20190391134
    Abstract: This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.
    Type: Application
    Filed: October 27, 2017
    Publication date: December 26, 2019
    Inventors: Daniel Haber, Shyamala Maheswaran, Tanya Todorova, Mark Kalinich, David Tomoaki Miyamoto, Xin Hong
  • Digital Analysis of Circulating Tumor Cells in Blood Samples
    Publication number: 20180057889
    Abstract: This disclosure relates to new assay methods for analysis of circulating tumor cells (CTCs) in blood samples for detection, e.g., early detection, and/or monitoring of disease, e.g., cancer. The methods provide ultra-high sensitivity and specificity, and include the use of microfluidic isolation of CTCs and digital detection of RNA derived from the CTCs.
    Type: Application
    Filed: March 25, 2016
    Publication date: March 1, 2018
    Inventors: Daniel A. Haber, Ravi Kapur, Mehmet Toner, Shyamala Maheswaran, Xin Hong, David Tomoaki Miyamoto, Tanya Todorova, Sarah Javaid